Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
AI 90-DAY FORECAST
NEUTRAL SIGNAL
██.█% Sign up free to reveal

Vireo Growth Inc. (VREOF) AI Forecast

Our AI analyzed Vireo Growth Inc.. Create a free account and follow it to see the 90-day price prediction.

Free account • 30-day free trial

$VREOF Neutral Signal Full forecast available

Vireo Growth Inc. (VREOF) Stock Forecast 2025


Vireo Growth Inc. (VREOF) AI Stock Price Forecast & Investment Analysis

Vireo Growth Inc. Stock Price Chart and Technical Analysis

Loading chart...

Vireo Growth Inc. (VREOF) - Comprehensive Stock Analysis & Investment Research

Deep dive into Vireo Growth Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on July 27, 2026, 9:04 p.m. (UTC)

Vireo Growth Inc. Investment Summary

When evaluating whether Vireo Growth Inc. (VREOF) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Vireo Growth Inc. (VREOF) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry. . With a market capitalization of $491 million, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.

Financial Performance Analysis

Our comprehensive financial analysis covers Vireo Growth Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Vireo Growth Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Vireo Growth Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Vireo Growth Inc.

Sign Up Free
Corporate Identity

Vireo Growth Inc. (Stock Symbol: VREOF) is a prominent company operating within the Life Sciences sector, with a specific focus on the Pharmaceutical Preparations industry. .

Leadership & Workforce

Detailed information about Vireo Growth Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Vireo Growth Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Vireo Growth Inc....

Unlock Full Company Profile

Get complete details about Vireo Growth Inc.

Sign Up Free
Revenue & Growth Analysis

Vireo Growth Inc. generates annual revenues of $350 million , representing an emerging company in its growth phase.

Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Vireo Growth Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Vireo Growth Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Vireo Growth Inc....

Unlock Financial Analysis

Get complete financial metrics for Vireo Growth Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Vireo Growth Inc.'s AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial

30-day free trial • Cancel anytime

Strategic Market Position

Vireo Growth Inc. strategically competes in the highly dynamic Pharmaceutical Preparations marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.

Industry Competitive Landscape

Vireo Growth Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company currently shows negative free cash flow of $-19 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.

Margin & Pricing Power Analysis

The company maintains a 42.6% gross margin indicating healthy pricing power relative to direct production costs. This margin level suggests the company has successfully differentiated its products or services, allowing it to command prices meaningfully above input costs. Maintaining these margins requires ongoing investment in brand, technology, or other differentiating factors.

Operating margin of -38.8% demonstrates how efficiently the company converts revenues into operating profits after accounting for all operating expenses including research and development, sales and marketing, and general administrative costs. Operating margin compression relative to gross margin suggests high operating expenses that may warrant efficiency improvements or reflect necessary growth investments.

Asset Utilization Efficiency

Asset turnover ratio of 0.38x indicates lower asset turnover that may reflect the industry's capital-intensive nature or potentially underutilized assets. Companies with low turnover typically depend on strong margins to generate adequate returns on capital.

Financial Strength & Leverage

Current ratio of 1.20 indicates adequate liquidity to meet short-term obligations with reasonable cushion. This level balances working capital efficiency with financial safety.

Vireo Growth Inc. (VREOF) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Vireo Growth Inc. stock analysis.

Deep dive into Vireo Growth Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Vireo Growth Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Vireo Growth Inc.:

P/B Ratio 1.67x
Market Cap $491M
Book Value/Share $5.97
Revenue/Share $7.11
FCF/Share $-0.39
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Vireo Growth Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Vireo Growth Inc.: An ROE of -9.5% indicates room for improvement in shareholder value creation.

ROE -9.5%
ROA -3.0%
ROIC -2.9%
Gross Margin 42.6%
Operating Margin -38.8%
Net Margin -53.0%
EBT Margin -41.6%
Tax Rate -31.6%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Vireo Growth Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Vireo Growth Inc.: A current ratio of 1.20 shows adequate liquidity.

Current Ratio 1.20x
Quick Ratio 0.84x
D/E Ratio 2.16x
Financial Leverage 3.16x
Interest Coverage 1.1x
Working Capital $42M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Vireo Growth Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Vireo Growth Inc.: Free cash flow of $-19M indicates cash challenges that need attention.

Operating Cash Flow -$20M
Free Cash Flow -$19M
Capital Spending $860K
FCF/Sales -5.4%
CapEx/Sales 0.2%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Vireo Growth Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Vireo Growth Inc.: An asset turnover of 0.38x suggests room for improvement in asset utilization.

Asset Turnover 0.38x
Receivables Turnover 24.9x
Inventory Turnover 0.4x
Fixed Assets Turnover 2.4x
Days Sales Outstanding 15 days
Days Inventory 925 days
Payables Period 304 days
Cash Conversion Cycle 636 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Vireo Growth Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Vireo Growth Inc.: With annual revenue of $350M, Vireo Growth Inc. demonstrates solid business size.

Income Statement
Total Revenue $350M
Operating Income -$20M
Net Income -$27M
SG&A Expense $32M
Cost of Goods Sold $30M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 258%
Cash & Short-term Investments 138%
Total Liabilities 635%
Short-term Debt 191%
Accounts Receivable 14%
Inventory 76%
Dividend & Shareholder Information
Shares Outstanding 49M
Growth Metrics (YoY)
Net Income Growth -53.0%

Latest Vireo Growth Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Vireo Growth Inc. (VREOF) stock price and investment outlook.

📰 Loading...

Vireo Growth Inc. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Vireo Growth Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
AARD ██% $146M x 1.7x
ABBV ██% $454.62B 125.1x x
ABCL ██% $1.60B x 1.7x
ABEO ██% $349M 5.3x 2.4x
ABT ██% $182.14B 29.0x 3.5x
ABUS ██% $869M 5.4x 3.3x
ABVC ██% $26M x 2.4x
ABVX ██% $10.05B x x
ACAD ██% $4.34B 11.6x 3.5x
ACET ██% $79M x 0.6x
ACRS ██% $750M x 5.2x
ACRV ██% $60M x 0.6x
ACUT ██% $4M x x
ACXP ██% $6M x 0.9x
ADAG ██% $233M x 6.2x
ADCT ██% $145M x x
ADIL ██% $6M x 1.7x
ADTX ██% $3M x x
ADXN ██% $7M x x
AEON ██% $11M x x
AGIO ██% $2.19B x 2.0x
AKBA ██% $343M x 12.5x
AKTX ██% $15M x 1.0x
ALDX ██% $96M x 2.3x
ALKS ██% $8.78B 57.5x 5.0x
ALLR ██% $19M x 2.8x
ALMS ██% $3.54B x 6.2x
ALNY ██% $36.85B 117.5x 46.7x
ALT ██% $576M x 2.0x
ALXO ██% $272M x 1.8x
ALZN ██% $5M x 7.0x
AMLX ██% $2.16B x 7.9x
AMPH ██% $842M 10.6x 1.1x
AMRN ██% $287M x 0.6x
AMRX ██% $5.68B 46.5x x
ANAB ██% $1.59B x 125.1x
ANEB ██% $12M x 1.6x
ANIP ██% $1.64B 17.8x 2.9x
ANIX ██% $116M x 8.0x
ANNX ██% $807M x 4.0x
ANRO ██% $941M x 3.9x
ANTX ██% $177M x 2.2x
ANVS ██% $74M x 23.8x
APLM ██% $41M x x
APRE ██% $8M x 0.2x
APUS ██% $8M x 0.1x
APVO ██% $5M x 0.5x
AQST ██% $468M x x
ARCT ██% $165M x 0.9x
ARDX ██% $1.27B x 8.5x
ARQT ██% $3.42B x 18.0x
ARTL ██% $4M x 0.5x
ARVN ██% $524M x 1.4x
ARWR ██% $12.20B x 19.9x
ASBP ██% $9M x 2.4x
ASMB ██% $500M x 2.5x
ASND ██% $15.66B x x
ASRT ██% $151M x 2.0x
ATAI ██% $2.65B x 16.6x
ATHE ██% $85M x x
ATNM ██% $28M x 12.1x
ATOS ██% $21M x 0.7x
ATXI ██% $910K x 0.8x
AUPH ██% $1.99B 6.7x 3.5x
AVBP ██% $1.43B x 4.4x
AVIR ██% $388M x 1.7x
AVTX ██% $1.05B x 15.4x
AXIM ██% $1M x x
AXSM ██% $12.42B x 227.5x
AZTR ██% $2M x 0.2x
BBIO ██% $16.23B x x
BBOT ██% $711M x 1.9x
BCAX ██% $1.82B x 3.5x
BCTX ██% $32M x 1.3x
BCYC ██% $290M x 0.5x
BDPT ██% $10K x x
BDRX ██% $2M x x
BFRG ██% $11M x 2.3x
BFRI ██% $13M x 2.1x
BHC ██% $1.72B x x
BHST ██% $45M x 1.8x
BIOA ██% $972M x 2.6x
BIOE ██% $13M 9.7x x
BIOM ██% $510K x x
BIVI ██% $11M x 0.7x
BIXT ██% $3M x x
BLRX ██% $13M x x
BLTE ██% $6.10B x 7.9x
BMEA ██% $91M x 4.9x
BMRN ██% $11.38B 42.3x 1.8x
BMY ██% $125.36B 17.2x 6.3x
BNTC ██% $396M x 2.2x
BOLD ██% $56M x 0.7x
BOLT ██% $7M x 0.4x
BPTH ██% $2M x x
BQST ██% $2M x x
BRNS ██% $25M x 0.4x
BSPK ██% $10K x x
BTAI ██% $24M x x
BYSI ██% $44M x x
CALC ██% $11M x x
CANF ██% $7M x 1.2x
CAPR ██% $1.14B x 4.1x
CATX ██% $336M x 1.0x
CBIO ██% $629M x 6.2x
CDT ██% $2M x x
CING ██% $62M x 3.3x
CLCS ██% $65M x x
CLNN ██% $65M x x
CLRB ██% $20M x 5.9x
CLSDQ ██% $1M x x
CLYM ██% $731M x 4.9x
CMMB ██% $10M x 0.8x
CMND ██% $2M x x
CMPS ██% $1.58B x 4.8x
CNBX ██% N/A x x
CNSP ██% $8M x 111.8x
CNTA ██% $6.27B x 12.9x
CNTB ██% $138M x 3.2x
CNTX ██% $54M x 1.0x
COCP ██% $13M x 3.1x
COGT ██% $6.87B x 11.3x
COLL ██% $1.15B 15.4x 3.7x
CORT ██% $10.09B 213.2x 15.8x
COYA ██% $103M x 2.1x
CPHI ██% $75M x 2.0x
CPIX ██% $102M x 4.7x
CPMD ██% $1M x x
CPRX ██% $3.85B 17.4x 3.8x
CRBP ██% $165M x 1.3x
CRMD ██% $631M 3.5x 1.4x
CRNX ██% $8.81B x 6.9x
CRVO ██% $25M x 2.3x
CRVS ██% $1.15B x 4.8x
CTMX ██% $725M x 2.3x
CTNM ██% $537M x 2.2x
CTOR ██% $54M x 1.5x
CTTH ██% $4M x 5.3x
CTXR ██% $14M x 0.2x
CUE ██% $136M x 6.3x
CURX ██% $6M x 0.7x
CVKD ██% $6M x 3.5x
CVSI ██% $4M x 2.6x
CYCN ██% $15M x 2.3x
CYDY ██% $285M x x
CYPH ██% $62M x 0.7x
CYRX ██% $759M 9.5x 1.5x
CYTK ██% $11.12B x x
DARE ██% $18M x 25.0x
DCOY ██% $3M x 0.7x
DERM ██% $180M x 5.8x
DMAC ██% $367M x 7.8x
DMRA ██% $1.83B x 3.6x
DNTH ██% $5.72B x 4.8x
DRMA ██% $5M x 0.8x
DRUG ██% $700M x x
DSGN ██% $726M x 3.3x
DWTX ██% $51M x 0.6x
DYN ██% $3.95B x 4.6x
EBS ██% $388M x 0.7x
EDSA ██% $50M x 4.9x
ELAB ██% $4M x 0.3x
ELAN ██% $12.37B x 1.9x
ELDN ██% $284M x 6.3x
ELTP ██% $409M 9.1x 4.1x
ELTX ██% $83M x x
ELVN ██% $3.77B x 8.3x
EMMA ██% $820K x x
ENLV ██% $73M 0.0x 0.0x
ENSC ██% $4M x x
ENTA ██% $376M x 3.2x
ENVB ██% $5M x 1.1x
EOLS ██% $404M x x
EPRX ██% $412M x 5.0x
EQ ██% $161M x 2.7x
ERAS ██% $6.01B x 15.3x
ERNA ██% $5M x 0.7x
ESPR ██% $799M x x
ETON ██% $1.21B x 39.5x
ETST ██% $35M 7.2x 5.0x
EVFM ██% $1M x x
EVMN ██% $408M x 1.3x
EWTX ██% $4.45B x 9.0x
FBIO ██% $114M 0.9x 0.7x
FBLG ██% $4M x 1.5x
FBRX ██% $1.57B x 37.2x
FHTX ██% $298M x x
FLNA ██% $45M x 0.7x
FTH ██% $716M x x
FULC ██% $250M x 0.8x
GALT ██% $227M x x
GANX ██% $77M x 5.5x
GCAN ██% $260K x x
GDTC ██% $10M x x
GERN ██% $963M x 4.2x
GHRS ██% $1.73B x x
GLMD ██% $3M x 0.2x
GLSI ██% $193M x 36.7x
GNLX ██% $133M x 5.8x
GNPX ██% $4M x 0.2x
GOSS ██% $70M x x
GOVX ██% $4M x 8.9x
GPCR ██% $3.61B x 2.5x
GRCE ██% $39M x 0.6x
GRI ██% $3M x 0.3x
GRTX ██% $3.38B 22.7x 4646.0x
GSK ██% $101.62B x x
GTBP ██% $12M x 1.6x
GYRE ██% $670M x 6.6x
HCM ██% $1.88B 2.1x 1.5x
HCWB ██% $4M x 0.7x
HELP ██% $479M x x
HEPA ██% $1M x 0.7x
HIND ██% $15M x 2.2x
HOOK ██% $14M x 0.4x
HOWL ██% $17M x 1.4x
HRMY ██% $2.07B 14.2x 2.3x
HRTX ██% $87M x 9.6x
HSTC ██% $99M x 79.9x
HURA ██% $137M x 5.9x
HYFT ██% $55M x x
HYPD ██% $40M x 0.7x
IBIO ██% $70M x 0.9x
IBO ██% $46M x 4.0x
IDYA ██% $3.22B x 3.4x
IFRX ██% $255M x x
IGC ██% $27M x 4.4x
IMMP ██% $57M x x
IMMX ██% $626M x 7.4x
IMNM ██% $2.49B x 4.2x
IMNN ██% $6M x 1.8x
IMRN ██% $9M x x
IMRX ██% $284M x 1.4x
IMUX ██% $195M x 1.3x
INBP ██% $5M x 0.3x
INDP ██% $369M x 295.8x
INDV ██% $5.02B 19.9x x
INM ██% $10M x 1.4x
INO ██% $84M x 13.8x
INSM ██% $23.26B x 33.0x
INTI ██% $15M x x
INVA ██% $1.58B 3.1x 1.2x
IOBTQ ██% $70K x 0.1x
IONS ██% $9.27B x 18.9x
IRD ██% $241M x x
IRON ██% $2.87B x 4.2x
IRWD ██% $624M 6.1x x
ISCO ██% $2M x x
IVA ██% $1.07B x x
IXHL ██% $38M x 0.5x
JAGX ██% $5M x x
JANX ██% $957M x 1.0x
JAZZ ██% $15.78B 534.9x 3.5x
JBIO ██% $1.19B x 4.0x
JNJ ██% $624.17B 29.7x 7.4x
JUNS ██% $6M x x
KALA ██% $11M x 1.1x
KALV ██% $1.38B x x
KAPA ██% $6M x 1.2x
KAYS ██% $140K x x
KMDA ██% $401M x x
KNSA ██% $4.82B 66.0x 8.0x
KPRX ██% $10M x 0.7x
KPTI ██% $160M x x
KROS ██% $200M x 0.7x
KRRO ██% $166M x 1.4x
KTTA ██% $16M x 0.3x
KURA ██% $928M x 8.6x
KYNB ██% $29M 0.2x x
LAB ██% $343M 4.4x 0.6x
LBRX ██% $993M x 2.6x
LEGN ██% $4.55B x x
LEXX ██% $14M x 3.0x
LFCR ██% $166M x x
LFVN ██% $79M 10.0x 2.4x
LGND ██% $6.05B 39.4x 6.1x
LGVN ██% $19M x 1.2x
LIANY ██% $12M x 0.1x
LIFD ██% $3M x 0.4x
LIPO ██% $150K x 0.1x
LITS ██% $35M x 0.6x
LIXT ██% $120M x 15.2x
LKFT ██% $1.85B x x
LLY ██% $1.07T 42.4x 34.4x
LNAI ██% $11M x x
LPCN ██% $16M x 0.7x
LQDA ██% $7.86B 352.5x 72.4x
LRMR ██% $403M x 2.6x
LSTA ██% $19M x 1.8x
LTRN ██% $32M x 9.4x
LXRX ██% $943M x 4.7x
LYEL ██% $298M x 1.1x
MAIA ██% $78M x 2.8x
MANE ██% $4.84B x 12.4x
MBIO ██% $4M x 0.5x
MBRX ██% $16M x 1.0x
MBX ██% $3.02B x 6.9x
MCRB ██% $50M x 1.9x
MDCX ██% $22M x 16.4x
MDGL ██% $12.52B x 23.0x
MGNX ██% $255M x 12.0x
MIRA ██% $39M x 4.2x
MIRM ██% $6.97B x 28.7x
MIST ██% $141M x 3.9x
MLTX ██% $1.62B x 6.4x
MLYS ██% $2.23B x 3.5x
MNKD ██% $1.20B x x
MNOV ██% $64M x 1.6x
MNPR ██% $708M x 5.2x
MPLT ██% $1.59B x 4.0x
MREO ██% $46M x 1.4x
MRK ██% $322.55B 36.1x 7.0x
MRKR ██% $20M x 1.5x
MRVI ██% $2.60B x 12.3x
MSLE ██% $200M x x
MTNB ██% $2M x 0.5x
MTVA ██% $8M x 0.9x
NAMS ██% $3.56B x 5.4x
NATR ██% $360M 18.1x 2.2x
NBP ██% $205M x 0.8x
NBTX ██% $1.91B x x
NCEL ██% $20M x 37.7x
NCNA ██% $6M x x
NERV ██% $195M x x
NEUP ██% $21M x 0.7x
NGNE ██% $710M x 3.0x
NIKA ██% $806M x x
NKTR ██% $2.34B x 4.1x
NKTX ██% $171M x 0.6x
NMAD ██% $89M x 11.2x
NNVC ██% $33M x 3.6x
NRIX ██% $2.46B x 6.1x
NRSN ██% $24M x x
NRXP ██% $176M x x
NSRX ██% $36M x 13.1x
NTHI ██% $90M x x
NUVB ██% $2.25B x 7.0x
NUVL ██% $9.75B x 8.3x
NVCT ██% $635M x 44.7x
NVS ██% $297.94B x x
NWBO ██% $273M x x
NXTC ██% $17M x 0.6x
NXTS ██% $3M x 0.2x
OCUL ██% $1.89B x 3.2x
OGEN ██% $2M x 0.4x
OGI ██% $130M x x
OGN ██% $3.56B 14.5x 3.9x
OKUR ██% $170M x 0.9x
OLMA ██% $1.03B x 2.1x
OMER ██% $740M 8.6x x
ONC ██% $33.90B 66.1x 7.1x
ONCO ██% $3M x 0.3x
ONCY ██% $99M x x
OPK ██% $888M x 0.7x
ORGO ██% $313M 115.0x 1.3x
ORIC ██% $1.13B x 2.7x
ORKA ██% $5.55B x 11.4x
ORMP ██% $170M 1.6x 0.7x
OSTX ██% $61M x x
OTLC ██% $13M x 0.1x
OVID ██% $401M x 2.0x
OWPC ██% $110K x x
PAHC ██% $1.38B 14.5x 3.8x
PBH ██% $2.37B 12.5x 1.3x
PBM ██% $11M x x
PBYI ██% $408M 16.7x 3.2x
PCRX ██% $1.02B 198.4x 1.6x
PCSA ██% $8M x 3.0x
PCYN ██% $2M x 1.0x
PDSB ██% $39M x 10.1x
PEPG ██% $145M x 1.1x
PFE ██% $142.33B 19.0x 1.6x
PGEN ██% $1.97B x 97.4x
PHAT ██% $922M x x
PHIO ██% $12M x 0.8x
PHVS ██% $2.32B x x
PKTX ██% $3M x 10.3x
PLRX ██% $67M x 0.4x
PLYX ██% $100M x 40.2x
PMHS ██% $2M x x
PMN ██% $113M x 1.9x
PMVP ██% $71M x 0.8x
PPBT ██% $1M x x
PPCB ██% $3M x 0.3x
PRAX ██% $8.98B x 6.4x
PRFX ██% $4M x 0.4x
PRGO ██% $1.39B x 0.6x
PRLD ██% $324M x 5.4x
PRPH ██% $840K x 0.1x
PRQR ██% $253M x x
PRTA ██% $453M x 1.5x
PTCT ██% $6.50B x x
PTGX ██% $8.70B x 13.3x
PTIX ██% $420K x x
PTN ██% $14M x 1.4x
PTPI ██% $170K 0.0x 0.1x
PULM ██% $6M x 1.8x
PVCT ██% $26M x x
PVLA ██% $2.05B x 8.8x
PYXS ██% $168M x 5.4x
QNRX ██% $9M x 1.0x
QNTM ██% $21M x x
QTTB ██% $457M 13.7x 9.9x
QUCY ██% $25M x 5.5x
QURE ██% $2.49B x 16.6x
RADX ██% $34M x x
RANI ██% $122M x 4.3x
RAPP ██% $1.98B x 4.2x
RARE ██% $2.66B x x
RCKT ██% $358M x 1.5x
RCUS ██% $3.67B x 7.0x
RDY ██% $9.85B x x
REGN ██% $67.80B 15.3x 2.2x
REVB ██% $4M x 0.3x
RFL ██% $118M x 1.6x
RGBP ██% $80K x x
RIGL ██% $678M 1.9x 1.7x
RKTO ██% $19M x 4.5x
RLMD ██% $546M x 2.5x
RLYB ██% $87M x 1.7x
RMHI ██% $25M x x
RMTI ██% $27M x 0.7x
RNAC ██% $229M x x
RNAZ ██% $7M x 5.5x
RNTX ██% $68M x 5.9x
RNXT ██% $43M x 3.8x
ROIV ██% $25.28B x 5.6x
RPRX ██% $33.99B 41.1x 4.9x
RTEZ ██% $1.93B x x
RVPH ██% $6M x 0.4x
RVRC ██% $101M x 16.5x
RYTM ██% $7.03B x 57.2x
RZLT ██% $466M x 4.0x
SBFM ██% $3M x 0.1x
SCNX ██% $16M x 0.2x
SCYX ██% $290M x 7.0x
SDEV ██% $30M 0.1x 0.2x
SDGR ██% $1.12B x 3.6x
SEPN ██% $1.50B x 4.0x
SER ██% $31M x 1.8x
SGMT ██% $433M x 4.2x
SHPH ██% $2M x 0.5x
SIGA ██% $228M 11.3x 1.5x
SILO ██% $5M x 0.9x
SION ██% $2.14B x 7.4x
SKVI ██% $1M x x
SKYE ██% $24M x 2.6x
SLGL ██% $261M x 11.5x
SLN ██% $541M x 11.0x
SLS ██% $2.24B x 20.8x
SMMT ██% $11.88B x 18.9x
SMNR ██% $157M x x
SNDX ██% $1.90B x 45.6x
SNGX ██% $5M x 1.8x
SNSE ██% $31M x x
SNY ██% $106.10B x x
SPRB ██% $124M x 3.6x
SPRC ██% $3M x x
SPRO ██% $69M 4.5x 1.3x
SPRY ██% $596M x 9.7x
SRPT ██% $1.73B 26.6x 1.2x
STOK ██% $1.89B x 4.8x
STTK ██% $702M x 7.3x
SUPN ██% $2.75B x 2.6x
SVRA ██% $1.16B x 6.6x
SXTP ██% $4M x 0.9x
SYBX ██% $8M x 0.6x
SYRE ██% $7.88B x 11.7x
TAK ██% $55.84B x x
TBPH ██% $870M 7.6x 3.0x
TCRT ██% $5M x 3.5x
TELO ██% $82M x 16.5x
TENX ██% $416M x 3.6x
TEVA ██% $36.16B 23.1x 4.4x
TGTX ██% $8.68B 18.8x 14.9x
TLPH ██% $65M x 3.5x
TLX ██% $3.38B x x
TNGX ██% $4.37B x 11.2x
TNXP ██% $165M x 0.7x
TOVX ██% $10M x 0.7x
TPST ██% $15M x 18.3x
TRDA ██% $236M x 0.9x
TRVI ██% $2.31B x 13.4x
TTRX ██% $243M x 39.7x
TVRD ██% $23M x 1.6x
TVTX ██% $5.27B x 53.4x
TXMD ██% $24M 132.6x 0.9x
TYRA ██% $1.89B x 4.9x
UNCY ██% $131M x 3.5x
UPB ██% $344M x 1.1x
URGN ██% $1.99B x x
UTHR ██% $26.39B 20.5x 4.5x
VBIO ██% $900K x 0.1x
VCNX ██% $3M x x
VERA ██% $2.54B x 5.1x
VGLS ██% $240K x x
VICP ██% $47M x x
VKTX ██% $4.04B x 8.1x
VNDA ██% $319M x 1.1x
VRCA ██% $87M x 5.4x
VRDN ██% $2.05B x 3.2x
VREOD ██% $491M x 1.7x
VREOF ██% $491M x 1.7x
VRTX ██% $122.36B 28.2x 6.3x
VSTM ██% $551M x 6.7x
VTGN ██% $9M x 0.2x
VTRS ██% $20.28B x 1.4x
VYNE ██% $17M x 0.7x
WHWK ██% $174M x 1.5x
WVE ██% $1.15B x 2.2x
XBIO ██% $6M x 0.8x
XBIT ██% $69M x 0.5x
XCUR ██% $11M x 5.2x
XENE ██% $6.28B x 4.7x
XERS ██% $1.45B 120.6x 111.3x
XLO ██% $58M x 0.8x
XNCR ██% $1.48B x 2.9x
XOMA ██% $710M 21.0x 7.7x
XTLB ██% $7M x x
ZBIO ██% $2.07B x 6.2x
ZLAB ██% $2.09B x 3.2x
ZNTL ██% $321M x 1.8x
ZTS ██% $32.38B 12.3x 10.0x
ZVRA ██% $571M 4.6x 2.8x
ZVSA ██% $940K x x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Vireo Growth Inc. Stock Forecast

How accurate are Vireo Growth Inc. stock predictions?

Our AI model shows a 12% Spearman correlation coefficient for VREOF predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Vireo Growth Inc. stock price forecasts?

Our analysis considers Vireo Growth Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Vireo Growth Inc. a good investment in 2025?

Based on our AI analysis, Vireo Growth Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Vireo Growth Inc. forecasts updated?

Vireo Growth Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Vireo Growth Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...